BioCentury
ARTICLE | Product Development

Translating LINGO

Hypotheses about the reasons for Biogen's LINGO miss in MS

June 20, 2016 7:00 AM UTC

Biogen Inc. isn't talking yet about why its anti-LINGO mAb failed a Phase II trial in the high-priority indication of multiple sclerosis, but translational researchers in the field have some ideas about knowledge gaps that may have contributed to the miss.

These include open questions about the time points at which it would be best to inhibit LINGO in the course of a flare or the course of disease, how central a role LINGO plays in remyelination, how much antibody needs to get across the blood-brain barrier, and the best ways to assess whether inhibiting LINGO is having the desired effect...